THE ZEBRAFISH: DISEASE MODELS AND CHEMICAL SCREENS, 4TH EDITION



Edited by H. William Detrich III, Monte Westerfield, and Leonard I. Zon



Methods in Cell Biology

The Zebrafish: Disease Models and Chemical Screens

Volume 138

Edited by

H. William Detrich, III


Northeastern University Marine Science Center Nahant, MA

Monte Westerfield

University of Oregon Institute of Neuroscience Eugene, OR

Leonard I. Zon

Harvard University Children's Hospital Boston, MA







Academic Press is an imprint of Elsevier
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
525 B Street, Suite 1800, San Diego, CA 92101-4495, United States
125 London Wall, London EC2Y 5AS, United Kingdom
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Fourth edition 2017

Copyright © 2011, 2017 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-803473-6

ISSN: 0091-679X

For information on all Academic Press publications visit our website at https://www.elsevier.com



Publisher: Zoe Kruze

Acquisition Editor: Zoe Kruze

Editorial Project Manager: Hannah Colford

Production Project Manager: Surya Narayanan Jayachandran

Designer: Victoria Pearson

Typeset by TNQ Books and Journals

Methods in Cell Biology

The Zebrafish: Disease Models and Chemical Screens

Volume 138

Series Editors

Leslie Wilson

Department of Molecular, Cellular and Developmental Biology University of California Santa Barbara, California

Phong Tran

University of Pennsylvania Philadelphia, USA & Institut Curie, Paris, France Len, Monte, and I dedicate the 4th Edition of Methods in Cell Biology: The Zebrafish to the postdoctoral fellows and graduate students who conducted the genetic screens that established the zebrafish as a preeminent vertebrate model system for analysis of development.

Contributors

S.L. Amacher

The Ohio State University, Columbus, OH, United States

M. Ammerman

Harvard Medical School, Boston, MA, United States

F. Argenton

Università degli Studi di Padova, Padova, Italy

K.R. Astell

University of Edinburgh, Edinburgh, United Kingdom

J.W. Astin

University of Auckland, Auckland, New Zealand

B. Blanco-Sánchez

University of Oregon, Eugene, OR, United States

T. Boehm

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

J.W. Chen

Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States

L. Chen

Leiden University, Leiden, The Netherlands

A. Clément

University of Oregon, Eugene, OR, United States

K.E. Crosier

University of Auckland, Auckland, New Zealand

P.S. Crosier

University of Auckland, Auckland, New Zealand

P.D. Currie

Monash University, Clayton, VIC, Australia

M. Dang

Harvard Medical School, Boston, MA, United States

M. D'Rozario

Washington University School of Medicine, St. Louis, MO, United States

L. Du

University of Auckland, Auckland, New Zealand

S.C. Eames Nalle

Genentech, Inc., South San Francisco, CA, United States

J.S. Eisen

University of Oregon, Eugene, OR, Unites States

B. Ewa Snaar-Jagalska

Leiden University, Leiden, The Netherlands

Y. Feng

University of Edinburgh, Edinburgh, United Kingdom

J.M. Frame

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

K.F. Franse

Appalachian State University, Boone, NC, United States

K.A. Gabor

National Institute of Environmental Health Sciences, Durham, NC, United States

J.L. Galloway

Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States

J.M. Gansner

Harvard Medical School, Boston, MA, United States

S. Gomez De La Torre Canny

Duke University, Durham, NC, United States

D. Greenald

University of Sheffield, Sheffield, United Kingdom

A. Groenewoud

Leiden University, Leiden, The Netherlands

K. Guillemin

University of Oregon, Eugene, OR, Unites States; Canadian Institute for Advanced Research, Toronto, ON, Canada

C.J. Hall

University of Auckland, Auckland, New Zealand

M.P. Harris

Harvard Medical School, Boston, MA, United States

M.N. Hayes

Massachusetts General Hospital, Boston, MA, United States; Massachusetts General Hospital, Charlestown, MA, United States; Harvard Stem Cell Institute, Boston, MA, United States

S. He

Harvard Medical School, Boston, MA, United States

I. Hess

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

K.J. Hromowyk

The Ohio State University, Columbus, OH, United States

A. Huysseune

Ghent University, Ghent, Belgium

N. Iwanami

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

C.-B. Jing

Harvard Medical School, Boston, MA, United States

D. Jurczyszak

University of Maine, Orono, ME, United States

P. Keerthisinghe

University of Auckland, Auckland, New Zealand

L. Kelly

University of Edinburgh, Edinburgh, United Kingdom

M. Kelly

University of Oregon, Eugene, OR, Unites States

C.H. Kim

University of Maine, Orono, ME, United States

H.R. Kim

University of Sheffield, Sheffield, United Kingdom

M.D. Kinkel

Appalachian State University, Boone, NC, United States

M. Kruithof-de Julio

University of Bern, Bern, Switzerland; Leiden University Medical Centre, Leiden, The Netherlands

D.M. Langenau

Massachusetts General Hospital, Boston, MA, United States; Massachusetts General Hospital, Charlestown, MA, United States; Harvard Stem Cell Institute, Boston, MA, United States

D.W. Laux

University of Edinburgh, Edinburgh, United Kingdom

M. Li

Monash University, Clayton, VIC, Australia

S.-E. Lim

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

A.T. Look

Harvard Medical School, Boston, MA, United States

E. Markham

University of Sheffield, Sheffield, United Kingdom

M.A. Matty

Duke University School of Medicine, Durham, NC, United States

E. Melancon

University of Oregon, Eugene, OR, Unites States

P.J. Millard

University of Maine, Orono, ME, United States

J.E.N. Minchin

University of Edinburgh, Edinburgh, United Kingdom; Duke University, Durham, NC, United States

K.R. Monk

Washington University School of Medicine, St. Louis, MO, United States; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, United States

T.E. North

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; Harvard Stem Cell Institute, Cambridge, MA, United States

M. Pack

University of Pennsylvania, Philadelphia, PA, United States

Y. Padberg

Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, University of Münster, Münster, Germany; Cells-in-Motion Cluster of Excellence (EXC M 1003-CiM), University of Münster, Münster, Germany

Barry H. Paw

Brigham & Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Dana-Farber Cancer Institute, Boston, MA, United States; Boston Children's Hospital, Boston, MA, United States

S.C. Petersen

Kenyon College, Gambier, OH, United States

J.B. Phillips

University of Oregon, Eugene, OR, United States

T. Ramezani

University of Edinburgh, Edinburgh, United Kingdom

J.F. Rawls

Duke University, Durham, NC, United States

S.E. Redfield

Stem Cell Program and Division of Hematology and Oncology, Childrens' Hospital Boston, Dana-Farber Cancer Institute, Howard Hughes Medical Institute and Harvard Medical School, Boston, MA, United States

I. Ribeiro Bravo

University of Edinburgh, Edinburgh, United Kingdom

L.E. Sanderson

Universite libre de Bruxelles, Gosselies, Belgium

K. Santhakumar

SRM University, Kattankulathur, India

M. Schorpp

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

S. Schulte-Merker

Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, University of Münster, Münster, Germany; Cells-in-Motion Cluster of Excellence (EXC M 1003-CiM), University of Münster, Münster, Germany

S. Sichel

University of Oregon, Eugene, OR, Unites States

D. Sieger

University of Edinburgh, Edinburgh, United Kingdom

C. Sullivan

University of Maine, Orono, ME, United States

D.M. Tobin

Duke University School of Medicine, Durham, NC, United States

C. Tulotta

Leiden University, Leiden, The Netherlands

G. van der Horst

Leiden University Medical Centre, Leiden, The Netherlands

G. van der Pluijm

Leiden University Medical Centre, Leiden, The Netherlands

Lisa N. van der Vorm

Brigham & Women's Hospital, Boston, MA, United States

F. van Eeden

University of Sheffield, Sheffield, United Kingdom

A. van Impel

Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, University of Münster, Münster, Germany; Cells-in-Motion Cluster of Excellence (EXC M 1003-CiM), University of Münster, Münster, Germany

A. Vettori

Università degli Studi di Padova, Padova, Italy

M. Westerfield

University of Oregon, Eugene, OR, United States

T.J. Wiles

University of Oregon, Eugene, OR, Unites States

D.S. Wiley

Stem Cell Program and Division of Hematology and Oncology, Childrens' Hospital Boston, Dana-Farber Cancer Institute, Howard Hughes Medical Institute and Harvard Medical School, Boston, MA, United States

C. Winkler

National University of Singapore, Singapore, Singapore

P.E. Witten

Ghent University, Ghent, Belgium

X. Zhao

University of Pennsylvania, Philadelphia, PA, United States

L.I. Zon

Stem Cell Program and Division of Hematology and Oncology, Childrens' Hospital Boston, Dana-Farber Cancer Institute, Howard Hughes Medical Institute and Harvard Medical School, Boston, MA, United States

E. Zoni

University of Bern, Bern, Switzerland; Leiden University Medical Centre, Leiden, The Netherlands

Preface

Len, Monte, and I are pleased to introduce the Fourth Edition of *Methods in Cell Biology: The Zebrafish*. The advantages of the zebrafish, *Danio rerio*, are numerous, including its short generation time and high fecundity, external fertilization, and the optical transparency of the embryo. The ease of conducting forward genetic screens in the zebrafish, based on the pioneering work of George Streisinger, culminated in screens from the laboratories of Wolfgang Driever, Mark C. Fishman, and Christiane Nüsslein-Volhard, published in a seminal volume of *Development* (Volume 123, December 1, 1996) that described a "candy store" of mutants whose phenotypes spanned the gamut of developmental processes and mechanisms. Life for geneticists who study vertebrate development became *really* fine.

Statistics derived from ZFIN (The Zebrafish Model Organism Database; http://zfin.org/cgi-bin/webdriver?MIval=aa-ZDB_home.apg) illustrate the dramatic growth of research involving zebrafish. The zebrafish genome has been sequenced, and as of 2014, more than 25,000 genes have been placed on the assembly. Greater than 15,500 of these genes have been established as orthologs of human genes. The zebrafish community has grown from ~1400 researchers in 190 laboratories as of 1998 to ~7000 in 930 laboratories in 2014. The annual number of publications based on the zebrafish has risen from 1913 to 21,995 in the same timeframe. Clearly, the zebrafish has arrived as a vertebrate biomedical model system *par excellence*.

When we published the First Edition (Volumes 59 and 60) in 1998, our goal was to encourage biologists to adopt the zebrafish as a genetically tractable model organism for studying biological phenomena from the cellular through the organismal. Our goal today remains unchanged, but the range of subjects and the suite of methods have expanded rapidly and significantly in sophistication over the years. With the Second and Third Editions of *MCB*: The Zebrafish (Volumes 76 and 77 in 2004; Volumes 100, 101, 104, and 105 in 2010–11), we documented this extraordinary growth, again relying on the excellent chapters contributed by our generous colleagues in the zebrafish research community.

When Len, Monte, and I began planning the Fourth Edition, we found that the zebrafish community had once more developed and refined novel experimental systems and technologies to tackle challenging biological problems across the spectrum of the biosciences. We present these methods following the organizational structure of the Third Edition, with volumes devoted to Cellular and Developmental Biology, to Genetics, Genomics, and Transcriptomics, and to Disease Models and Chemical Screens. Here we introduce the fourth volume, Disease Models and Chemical Screens.

Disease Models and Chemical Screens covers major technical advances in development of the zebrafish as an important biomedical model organism. Nine sections are devoted to adipose tissue, the innate and adaptive immune systems, blood and lymph, visceral organs, the musculoskeletal system, central and sensory nervous systems, cancer, transplantation, and chemical screening. We anticipate that you,

our readership, will apply these methods successfully in your own zebrafish research programs and will develop your own disease models that may be considered for a future edition of *Methods in Cell Biology: The Zebrafish*.

We thank the series editors, Leslie Wilson and Phong Tran, and the staff of Elsevier/Academic Press, especially Zoe Kruze and Hannah Colford, for their enthusiastic support of our Fourth Edition. Their help, patience, and encouragement are profoundly appreciated.

H. William Detrich, III Monte Westerfield Leonard I. Zon

Contents

Contributors	xvii
Preface	xxiii
DADT I ADI	POSE TISSUE
PAKI I ADI	L02E 11220E
CHAPTER 1	In Vivo Imaging and Quantification of Regional
OHAI IER I	Adiposity in Zebrafish
	J.E.N. Minchin, J.F. Rawls
	Introduction
1	Rationale
	Materials
	Methods 11
	Summary 23
4.	Acknowledgments. 24
	References. 24
	References
PART II INI	NATE AND ADAPTIVE IMMUNE SYSTEMS
I AIXI II IIXI	TATE AND ADAI TIVE IMMONE STOTEMS
CHAPTER 2	Innate Immune Cells and Bacterial Infection in
Oliva TER E	Zebrafish31
	J.W. Astin, P. Keerthisinghe, L. Du, L.E. Sanderson,
	K.E. Crosier, P.S. Crosier, C.J. Hall
	Introduction
1.	Quantifying the Innate Immune Cell Response to Bacterial
	Infection
2	Bioassays for Assessing Neutrophil Bactericidal Function42
	Bioassays for Assessing Macrophage Bactericidal Function 42
	Drug Discovery Platform to Identify New
٦.	Immunomodulatory Drugs
	Acknowledgments
	References
	Notice (1965)

CHAPTER 3	Best Practices for Germ-Free Derivation and Gnotobiotic Zebrafish Husbandry
	Introduction
	Experimental Procedures
2.	Prospectus. 89
3.	Solutions93
	Acknowledgments95
	References95
CHAPTER 4	Infectious Disease Models in Zebrafish
	P.J. Millard, D.M. Tobin, C.H. Kim
	Introduction
	Methods for Systemic Bacterial and Viral Infections 104
2.	Methods for Localized Bacterial and Viral Infections 123
	Conclusion
	References
CHAPTER 5	Live Imaging the Earliest Host Innate Immune Response to Preneoplastic Cells Using a Zebrafish Inducible KalTA4-ER ^{T2} /UAS
	System
	Introduction
1.	Generation of Preneoplastic Cell Clones Using the
	KalTA4-ER ^{T2} /UAS System in Zebrafish Larvae
2.	Live Imaging Preneoplastic Cell: Neutrophil Interaction
	Using Confocal Microscopy
3.	Image Analysis and 4D Reconstruction
	Conclusion
	Acknowledgments. 147
	References. 147

CHAPTER 6	Studying the Adaptive Immune System in Zebrafish by Transplantation of Hematopoietic Precursor Cells
	N. Iwanami, I. Hess, M. Schorpp, T. Boehm
	Introduction
1.	Methodology for the Transplantation of Hematopoietic Cells 155
2.	Discussion
3.	Future Directions
	Acknowledgments
	References
PART III BL	OOD AND LYMPH
CHAPTER 7	Hematopoietic Stem Cell Development: Using the
OHAI IER 7	Zebrafish to Identify Extrinsic and Intrinsic
	Mechanisms Regulating Hematopoiesis
	J.M. Frame, SE. Lim, T.E. North
	Introduction to Hematopoietic Development
1.	Use of Zebrafish to Investigate Hematopoietic Stem Cell
•	Development
2.	Zebrafish Tools and Protocols
	References
CHAPTER 8	Studying Disorders of Vertebrate Iron and Heme
	Metabolism Using Zebrafish 193
	Lisa N. van der Vorm, Barry H. Paw
1.	Overview of Vertebrate Cellular Iron and Heme
	Metabolism
2.	Advantageous Properties of Zebrafish to Study Genetics 196
	Tools to Study Iron and Heme Metabolism Using
	Zebrafish
	Conclusions and Future Directions
	Acknowledgments. 212
	References. 212